Optic Pathway Gliomas

  • Eveline Teresa Hidalgo
  • Cordelia Orillac
  • Jeffrey H. Wisoff
Living reference work entry


Optic pathway gliomas (OPGs) comprise a spectrum of neoplasms ranging from tubular thickening of the optic nerves to massive exophytic lesions diffusely involving the chiasm and/or hypothalamus, extending from the third ventricle to the prepontine cistern. OPGs constitute approximately 5% of pediatric brain tumors. The most common presentation in children is visual disturbances, but children can also present with neuroendocrinologic disturbances and, in children under the age of 1 year, diencephalic syndrome. Children affected by the genetic condition of neurofibromatosis 1 (NF1) have a predisposition to develop OPGs with up to 15% of patients with NF1 having the diagnosis of OPG. OPG in patients with NF1 may have a better prognosis than sporadic tumors.

There is a role for observation in the management of these tumors in patients without clinical or radiologic progression. Chemotherapy is often a first-line treatment in OPGs. The role of surgery includes diagnosis in select cases with atypical appearance, subtotal resection for decompression of the visual apparatus, and salvage therapy. Gross total resection is limited to unilateral intraorbital tumors; it is rarely if ever the goal of intracranial OPGs, since there is an unresectable intrinsic component of the tumor. Radiation can be considered in children with progressive disease after chemotherapy and in children older than 3 years. With multidisciplinary treatment most children will achieve a prolonged progression-free survival; however, subsequent tumor growth can result in complete loss of vision, additional endocrine deficiencies, neurologic deficits, and poor quality of life. Better strategies to identify tumors with high risk of progression and novel therapeutic targets are needed.


  1. Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR et al (2012) Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol 30(21):2641–2647CrossRefPubMedPubMedCentralGoogle Scholar
  2. Avery RA, Hardy KK (2014) Vision specific quality of life in children with optic pathway gliomas. J Neuro-Oncol 116(2):341–347CrossRefGoogle Scholar
  3. Avery RA, Hwang EI, Jakacki RI, Packer RJ (2014) Marked recovery of vision in children with optic pathway gliomas treated with bevacizumab. JAMA Ophthalmol 132(1):111–114CrossRefPubMedGoogle Scholar
  4. Banerjee A, Jakacki RI, Onar-Thomas A, Wu S, Nicolaides T, Young Poussaint T et al (2017) A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro-Oncology 19(8):1135–1144CrossRefPubMedPubMedCentralGoogle Scholar
  5. Blanchard G, Lafforgue MP, Lion-Francois L, Kemlin I, Rodriguez D, Castelnau P et al (2016) Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort. Eur J Paediatr Neurol 20(2):275–281CrossRefPubMedGoogle Scholar
  6. Campagna M, Opocher E, Viscardi E, Calderone M, Severino SM, Cermakova I et al (2010) Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1. Pediatr Blood Cancer 55(6):1083–1088CrossRefPubMedGoogle Scholar
  7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26): 2507–2516CrossRefPubMedPubMedCentralGoogle Scholar
  8. Chong AL, Pole JD, Scheinemann K, Hukin J, Tabori U, Huang A et al (2013) Optic pathway gliomas in adolescence – time to challenge treatment choices? Neuro-Oncology 15(3):391–400CrossRefPubMedGoogle Scholar
  9. Czyzyk E, Jozwiak S, Roszkowski M, Schwartz RA (2003) Optic pathway gliomas in children with and without neurofibromatosis 1. J Child Neurol 18(7):471–478CrossRefPubMedGoogle Scholar
  10. Diggs-Andrews KA, Brown JA, Gianino SM, Rubin JB, Wozniak DF, Gutmann DH (2014) Sex is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol 75(2): 309–316CrossRefPubMedPubMedCentralGoogle Scholar
  11. Dodgshun AJ, Elder JE, Hansford JR, Sullivan MJ (2015) Long-term visual outcome after chemotherapy for optic pathway glioma in children: site and age are strongly predictive. Cancer 121(23):4190–4196CrossRefPubMedGoogle Scholar
  12. Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ et al (2012) Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro-Oncology 14(6):790–797CrossRefPubMedPubMedCentralGoogle Scholar
  13. Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ et al (2014) Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. Ann Neurol 75(5):799–800CrossRefPubMedGoogle Scholar
  14. Gan HW, Phipps K, Aquilina K, Gaze MN, Hayward R, Spoudeas HA (2015) Neuroendocrine morbidity after pediatric optic gliomas: a longitudinal analysis of 166 children over 30 years. J Clin Endocrinol Metab 100(10):3787–3799CrossRefPubMedGoogle Scholar
  15. Goodden J, Pizer B, Pettorini B, Williams D, Blair J, Didi M et al (2014) The role of surgery in optic pathway/hypothalamic gliomas in children. J Neurosurg Pediatr 13(1):1–12CrossRefPubMedGoogle Scholar
  16. Grill J, Couanet D, Cappelli C, Habrand JL, Rodriguez D, Sainte-Rose C et al (1999) Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann Neurol 45(3):393–396CrossRefPubMedGoogle Scholar
  17. Grill J, Laithier V, Rodriguez D, Raquin MA, Pierre-Kahn A, Kalifa C (2000) When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr 159(9):692–696CrossRefPubMedGoogle Scholar
  18. Gutmann DH, Donahoe J, Brown T, James CD, Perry A (2000) Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol 26(4): 361–367CrossRefPubMedGoogle Scholar
  19. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358–365CrossRefGoogle Scholar
  20. Hsu TR, Wong TT, Chang FC, Ho DM, Tang RB, Thien PF et al (2008) Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children. Childs Nerv Syst 24(12):1457–1461CrossRefPubMedGoogle Scholar
  21. Jahraus CD, Tarbell NJ (2006) Optic pathway gliomas. Pediatr Blood Cancer 46(5):586–596CrossRefPubMedGoogle Scholar
  22. Jeon YK, Cheon JE, Kim SK, Wang KC, Cho BK, Park SH (2008) Clinicopathological features and global genomic copy number alterations of pilomyxoid astrocytoma in the hypothalamus/optic pathway: comparative analysis with pilocytic astrocytoma using array-based comparative genomic hybridization. Mod Pathol 21(11):1345–1356CrossRefPubMedGoogle Scholar
  23. Jones DT, Ichimura K, Liu L, Pearson DM, Plant K, Collins VP (2006) Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age. J Neuropathol Exp Neurol 65(11):1049–1058CrossRefPubMedPubMedCentralGoogle Scholar
  24. Jost SC, Ackerman JW, Garbow JR, Manwaring LP, Gutmann DH, McKinstry RC (2008) Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma. Pediatr Radiol 38(12):1293–1299CrossRefPubMedGoogle Scholar
  25. Kalin-Hajdu E, Decarie JC, Marzouki M, Carret AS, Ospina LH (2014) Visual acuity of children treated with chemotherapy for optic pathway gliomas. Pediatr Blood Cancer 61(2):223–227CrossRefPubMedGoogle Scholar
  26. Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH et al (2014) Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro-Oncology 16(10):1408–1416CrossRefPubMedPubMedCentralGoogle Scholar
  27. Khafaga Y, Hassounah M, Kandil A, Kanaan I, Allam A, El Husseiny G et al (2003) Optic gliomas: a retrospective analysis of 50 cases. Int J Radiat Oncol Biol Phys 56(3):807–812CrossRefPubMedGoogle Scholar
  28. Kilday JP, Bartels UK, Bouffet E (2014) Targeted therapy in pediatric low-grade glioma. Curr Neurol Neurosci Rep 14(4):441CrossRefPubMedGoogle Scholar
  29. Kirsch DG, Tarbell NJ (2004) New technologies in radiation therapy for pediatric brain tumors: the rationale for proton radiation therapy. Pediatr Blood Cancer 42(5):461–464CrossRefPubMedGoogle Scholar
  30. Kolar GR, Miller-Thomas MM, Schmidt RE, Simpson JR, Rich KM, Linette GP (2013) Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib. J Clin Oncol 31(3):e40–e43CrossRefPubMedGoogle Scholar
  31. Kwon Y, Bae JS, Kim JM, Lee DH, Kim SY, Ahn JS et al (2005) Visual changes after gamma knife surgery for optic nerve tumors. Report of three cases. J Neurosurg 102(Suppl):143–146CrossRefPubMedGoogle Scholar
  32. Lambron J, Rakotonjanahary J, Loisel D, Frampas E, De Carli E, Delion M et al (2016) Can we improve accuracy and reliability of MRI interpretation in children with optic pathway glioma? Proposal for a reproducible imaging classification. Neuroradiology 58(2):197–208CrossRefPubMedGoogle Scholar
  33. Lassaletta A, Zapotocky M, Mistry M, Ramaswamy V, Honnorat M, Krishnatry R et al (2017) Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 35(25):2934–2941CrossRefPubMedPubMedCentralGoogle Scholar
  34. Liang CL, Lu K, Liliang PC, Chen HJ (2010) Gamma knife surgery for optic glioma. Report of 2 cases. J Neurosurg 113(Suppl):44–47PubMedGoogle Scholar
  35. Listernick R, Charrow J, Greenwald M, Mets M (1994) Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 125(1):63–66CrossRefPubMedGoogle Scholar
  36. Liu GT (2006) Optic gliomas of the anterior visual pathway. Curr Opin Ophthalmol 17(5):427–431CrossRefPubMedGoogle Scholar
  37. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087–1095CrossRefGoogle Scholar
  38. Louis DN, International Agency for Research on Cancer, World Health Organization (2007) WHO classification of tumours of the central nervous system, 4th edn. International Agency for Research on Cancer, Lyon. 309 ppGoogle Scholar
  39. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. (2016) The 2016 World Health Organization classification of tumors of the central nervous system. Revised 4th edition. 408 pGoogle Scholar
  40. Mahoney DH Jr, Cohen ME, Friedman HS, Kepner JL, Gemer L, Langston JW et al (2000) Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro-Oncology 2(4):213–220CrossRefPubMedPubMedCentralGoogle Scholar
  41. Miller NR (2004) Primary tumours of the optic nerve and its sheath. Eye (Lond) 18(11):1026–1037CrossRefGoogle Scholar
  42. Millward CP, Perez Da Rosa S, Avula S, Ellenbogen JR, Spiteri M, Lewis E et al (2015) The role of early intra-operative MRI in partial resection of optic pathway/hypothalamic gliomas in children. Childs Nerv Syst 31(11):2055–2062CrossRefPubMedGoogle Scholar
  43. Nageswara Rao AA, Packer RJ (2014) Advances in the management of low-grade gliomas. Curr Oncol Rep 16(8):398CrossRefPubMedGoogle Scholar
  44. Nakamura M, Shimada K, Ishida E, Higuchi T, Nakase H, Sakaki T et al (2007) Molecular pathogenesis of pediatric astrocytic tumors. Neuro-Oncology 9(2):113–123CrossRefPubMedPubMedCentralGoogle Scholar
  45. Nicolin G, Parkin P, Mabbott D, Hargrave D, Bartels U, Tabori U et al (2009) Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer 53(7):1231–1237CrossRefPubMedGoogle Scholar
  46. Opocher E, Kremer LC, Da Dalt L, van de Wetering MD, Viscardi E, Caron HN et al (2006) Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer 42(12):1807–1816CrossRefPubMedGoogle Scholar
  47. Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS et al (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86(5):747–754CrossRefPubMedGoogle Scholar
  48. Penman CL, Faulkner C, Lowis SP, Kurian KM (2015) Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas. Front Oncol 5:54CrossRefPubMedPubMedCentralGoogle Scholar
  49. Plaza MJ, Borja MJ, Altman N, Saigal G (2013) Conventional and advanced MRI features of pediatric intracranial tumors: posterior fossa and suprasellar tumors. AJR Am J Roentgenol 200(5):1115–1124CrossRefPubMedGoogle Scholar
  50. Rakotonjanahary J, De Carli E, Delion M, Kalifa C, Grill J, Doz F et al (2015) Mortality in children with optic pathway glioma treated with up-front BB-SFOP chemotherapy. PLoS One 10(6):e0127676CrossRefPubMedPubMedCentralGoogle Scholar
  51. Rodriguez FJ, Lim KS, Bowers D, Eberhart CG (2013) Pathological and molecular advances in pediatric low-grade astrocytoma. Annu Rev Pathol 8:361–379CrossRefPubMedGoogle Scholar
  52. Ruge MI, Simon T, Suchorska B, Lehrke R, Hamisch C, Koerber F et al (2011) Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children: long-term outcome. J Clin Oncol 29(31):4151–4159CrossRefPubMedGoogle Scholar
  53. Schindera C, Wingeier K, Goeggel Simonetti B, Diepold M, Nauer CB, Fleischhauer J et al (2011) Macrocephaly in neurofibromatosis type 1: a sign post for optic pathway gliomas? Childs Nerv Syst 27(12):2107–2111CrossRefPubMedGoogle Scholar
  54. Shamji MF, Benoit BG (2007) Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications. Neurosurg Focus 23(5):E3CrossRefPubMedGoogle Scholar
  55. Shapey J, Danesh-Meyer HV, Kaye AH (2011) Diagnosis and management of optic nerve glioma. J Clin Neurosci 18(12):1585–1591CrossRefPubMedGoogle Scholar
  56. Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME et al (2006) Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 24(16):2570–2575CrossRefPubMedGoogle Scholar
  57. Shofty B, Weizman L, Joskowicz L, Constantini S, Kesler A, Ben-Bashat D et al (2011) MRI internal segmentation of optic pathway gliomas: clinical implementation of a novel algorithm. Childs Nerv Syst 27(8):1265–1272CrossRefPubMedGoogle Scholar
  58. Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N et al (2013) Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci USA 110(15):5957–5962CrossRefPubMedGoogle Scholar
  59. Taylor T, Jaspan T, Milano G, Gregson R, Parker T, Ritzmann T et al (2008) Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol 81(970):761–766CrossRefPubMedGoogle Scholar
  60. Tow SL, Chandela S, Miller NR, Avellino AM (2003) Long-term outcome in children with gliomas of the anterior visual pathway. Pediatr Neurol 28(4):262–270CrossRefPubMedGoogle Scholar
  61. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6): 855–867CrossRefPubMedGoogle Scholar
  62. Wan MJ, Ullrich NJ, Manley PE, Kieran MW, Goumnerova LC, Heidary G (2016) Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1. J Neurooncol 129:173CrossRefPubMedGoogle Scholar
  63. Wisoff JH (1992) Management of optic pathway tumors of childhood. Neurosurg Clin N Am 3(4):791–802PubMedCrossRefGoogle Scholar
  64. Yeom KW, Lober RM, Andre JB, Fisher PG, Barnes PD, Edwards MS et al (2013) Prognostic role for diffusion-weighted imaging of pediatric optic pathway glioma. J Neuro-Oncol 113(3): 479–483CrossRefGoogle Scholar
  65. Yoshikawa G, Nagata K, Kawamoto S, Tsutsumi K (2003) Remarkable regression of optic glioma in an infant. Case illustration. J Neurosurg 98(5):1134CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Eveline Teresa Hidalgo
    • 1
  • Cordelia Orillac
    • 1
  • Jeffrey H. Wisoff
    • 1
  1. 1.Division of Pediatric NeurosurgeryHassenfeld Children’s Hospital, NYU Langone HealthNew YorkUSA

Section editors and affiliations

  • James Thomas Rutka
    • 1
  1. 1.The Arthur and Sonia Labatt Brain Tumour Research CentreThe Hospital for Sick Children, The University of TorontoTorontoUSA

Personalised recommendations